101.66
前日終値:
$100.68
開ける:
$100.7
24時間の取引高:
14.37M
Relative Volume:
1.06
時価総額:
$177.07B
収益:
$46.59B
当期純損益:
$5.41B
株価収益率:
32.86
EPS:
3.0938
ネットキャッシュフロー:
$7.38B
1週間 パフォーマンス:
+10.37%
1か月 パフォーマンス:
+14.99%
6か月 パフォーマンス:
-16.08%
1年 パフォーマンス:
-17.80%
Abbott Laboratories Stock (ABT) Company Profile
名前
Abbott Laboratories
セクター
電話
(224) 667-6100
住所
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ABT
Abbott Laboratories
|
101.66 | 177.07B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
319.14 | 122.35B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
83.29 | 106.61B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
43.77 | 65.06B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
85.00 | 48.94B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-22 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 開始されました | The Benchmark Company | Buy |
| 2025-07-18 | アップグレード | Jefferies | Hold → Buy |
| 2025-06-16 | 開始されました | Leerink Partners | Market Perform |
| 2024-10-08 | 開始されました | Oppenheimer | Outperform |
| 2024-09-19 | 開始されました | Piper Sandler | Overweight |
| 2024-07-30 | ダウングレード | Edward Jones | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2023-07-21 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 繰り返されました | Barclays | Overweight |
| 2023-04-20 | 繰り返されました | Bernstein | Outperform |
| 2023-04-20 | 繰り返されました | JP Morgan | Overweight |
| 2023-04-20 | 繰り返されました | Raymond James | Outperform |
| 2023-04-20 | 繰り返されました | UBS | Buy |
| 2023-04-20 | 繰り返されました | Wolfe Research | Underperform |
| 2023-03-29 | 開始されました | UBS | Buy |
| 2022-10-26 | 開始されました | Mizuho | Neutral |
| 2022-10-18 | 開始されました | Barclays | Overweight |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-07-06 | 開始されました | Wolfe Research | Underperform |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-01-27 | 繰り返されました | Credit Suisse | Outperform |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-01-27 | 繰り返されました | Raymond James | Outperform |
| 2022-01-27 | 繰り返されました | UBS | Buy |
| 2021-12-10 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-10-27 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 開始されました | Redburn | Neutral |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Neutral |
| 2021-01-28 | アップグレード | BTIG Research | Neutral → Buy |
| 2020-09-11 | 開始されました | Wolfe Research | Outperform |
| 2020-06-01 | ダウングレード | Goldman | Neutral → Sell |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2020-02-13 | 開始されました | Goldman | Neutral |
| 2020-02-06 | 再開されました | BTIG Research | Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-06-13 | 繰り返されました | BofA/Merrill | Buy |
| 2019-02-07 | 繰り返されました | BofA/Merrill | Buy |
| 2019-01-02 | ダウングレード | Citigroup | Neutral → Sell |
| 2018-11-30 | アップグレード | Goldman | Neutral → Buy |
| 2018-10-16 | 開始されました | Barclays | Overweight |
| 2018-06-27 | 開始されました | Bernstein | Outperform |
| 2018-01-30 | 繰り返されました | Citigroup | Neutral |
| 2018-01-25 | 繰り返されました | Stifel | Buy |
| 2018-01-25 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 開始されました | Evercore ISI | Outperform |
| 2018-01-02 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-01-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-10-19 | 繰り返されました | Stifel | Buy |
すべてを表示
Abbott Laboratories (ABT) 最新ニュース
Lobbying Update: $1,150,000 of ABBOTT LABORATORIES lobbying was just disclosed - Quiver Quantitative
Abbott Laboratories stock trades steadily as diagnostics and medical devices underpin earnings momen - Ad-hoc-news.de
Craneware, Abbott Probe Separate Health Data Theft Incidents - BankInfoSecurity
Abbott Laboratories (NYSE:ABT) Faces A Major Medical Device Growth Test - Kalkine Media
ShinyHunters hit medial giant Abbott, disrupting cancer drug research and more - Yahoo Tech
Abbott Investigating Cyberattack Claims From Two Threat Actors - The HIPAA Journal
Healthcare giant Abbott probes two cyber incidents amid extortion claims - Malwarebytes
Abbott Laboratories investigates 2 separate cyber incidents - SC Media
Fairlife dairy cyberattack, ACR Stealer surge, Abbott Labs incidents - LinkedIn
Benchmark reiterates Buy on Abbott Labs stock, cites guidance raise - Investing.com
Abbott Laboratories stock trades steady as diagnostics and medical devices support growth - Ad-hoc-news.de
Cybersecurity News: Fairlife dairy cyberattack, ACR Stealer surge, Abbott Labs incidents - CISO Series
Abbott Laboratories Cybersecurity Breach Analysis: ShinyHunters Attack on Exact Sciences Systems and ShadowByt3$ LabCentral Portal Incident - Rescana
Abbott Investigates Two Separate Cyber Incidents, Says No Operations Affected - Insurance Journal
Abbott Laboratories stock holds firm as diagnostics and medical devices support earnings - ad-hoc-news.de
Medical giant Abbott investigates two cyber incidents as ShinyHunters claims breach - Cybernews
This Dividend ETF Yields 3.2% and Is Beating the Nasdaq-100 This Year - The Motley Fool
Abbott Laboratories (ABT) Stock Faces Margin Squeeze As Net Profit Slide Tests Growth Narrative - simplywall.st
Abbott Stock: Bear Trap Over, With Richer Return Prospects (NYSE:ABT) - Seeking Alpha
Abbott Just Showed Its Growth Engine Has More Than One Cylinder - Trefis
Abbott investigates two separate cyber incidents, says no operations affected By Reuters - Investing.com
Abbott investigates two cyber intrusions targeting cancer diagnostics and LabCentral portal - Межа. Новини України.
Abbott investigates two separate cyber incidents, says no operations affected - Reuters
Keysight Invalidates IRS Rule On GILTI, Abbott Says - Law360
US companies face rise in cyber attacks - Reuters
Bernstein Adjusts Price Target on Abbott Laboratories to $117 From $110, Maintains Outperform Rating - Moomoo
Abbott probes two cyber incidents amid extortion claims - BleepingComputer
Abbott discloses cyberattack on cancer diagnostics business - MedTech Dive
ABT Reiterated by Piper Sandler -- Price Target Raised to $118 - GuruFocus
Can Abbott Laboratories (NYSE:ABT) Extend Its Dividend Strength? - Kalkine Media
Abbott Laboratories Stock Surges 11% as Company Lifts Full Year Profit Guidance - TIKR.com
Abbott Laboratories Stock (ABT) Moved Up by 3.03% on Jul 17: Drivers Behind the Movement - TradingKey
ABT Q2 Earnings Call Flags Stronger Second-Half Setup - The Globe and Mail
These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results - Benzinga
Benchmark reiterates Buy on Abbott Labs stock, keeps $120 target - Investing.com
Piper Sandler Adjusts Price Target on Abbott Laboratories to $118 From $115, Maintains Overweight Rating - Moomoo
Can Abbott Stock Deliver on Its Second-Half Growth Promise? - Trefis
Abbott Laboratories stock could rise 40%+ by 20... - Pluang
JPMorgan Adjusts Price Target on Abbott Laboratories to $120 From $110, Maintains Overweight Rating - marketscreener.com
Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $112, Maintains Outperform Rating - marketscreener.com
Abbott Laboratories: Pick Up This Dividend King Deal Now - Seeking Alpha
Raising Dividends for 54 Consecutive Years to Reward Shareholders, Abbott Laboratories’ Diversified Layout Consolidates Its Growth Foundation - NAI500
What Helped Abbott Laboratories (NYSE:ABT) Raise Full-Year Outlook? - Kalkine Media
Abbott Laboratories (ABT) Could Be 15% Undervalued On Raised 2026 Earnings Outlook - simplywall.st
Why Abbott Stock Jumped Today - The Motley Fool
Abbott Laboratories Earnings Call Signals Broad-Based Momentum - TipRanks
ABT: Abbott Laboratories Exceeds Revenue and EPS Expectations, R - GuruFocus
Abbott Is On Deck to Launch Several New Devices - Morningstar
ABT: Abbott Laboratories Exceeds Expectations and Raises Profit Outlook - GuruFocus
Abbott Laboratories’s Stock Price Soars to $98.83, Enjoying a Robust 10.71% Uptick - Smartkarma
BTIG raises Abbott Labs stock price target to $134 on Q2 strength - Investing.com
Abbott Laboratories (ABT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):